Drug intelligence / Profile preview

Bp Mide Plus

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Bp Mide Plus is a combination pharmaceutical drug containing Amlodipine and Atenolol, primarily used for the treatment of hypertension (high blood pressure) and angina (heart-related chest pain). Amlodipine, a calcium channel blocker, works by relaxing and widening blood vessels, reducing the heart's workload. Atenolol, a beta-blocker, helps to slow the heart rate and reduce the force of heart contractions. This dual mechanism of action helps to lower blood pressure and improve blood flow to the heart, thereby reducing the risk of heart attack, stroke, and kidney problems. It is typically administered orally once daily.

Brand names: Bp Mide Plus

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)ADRB1 (β1)

Beyond the preview

Go deeper on Bp Mide Plus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bp Mide Plus.

Explore the full profile